|1.||Silver, Jerry: 8 articles (04/2015 - 04/2006)|
|2.||Ferrone, Soldano: 8 articles (11/2011 - 01/2004)|
|3.||Bassols, Anna: 7 articles (02/2011 - 02/2002)|
|4.||Tom, Veronica J: 6 articles (08/2015 - 05/2008)|
|5.||Levine, Joel M: 6 articles (12/2014 - 05/2002)|
|6.||Stallcup, William B: 5 articles (12/2014 - 04/2002)|
|7.||Snow, Diane M: 5 articles (02/2014 - 06/2002)|
|8.||Li, Shuxin: 4 articles (09/2015 - 02/2007)|
|9.||Wight, Thomas N: 4 articles (04/2014 - 05/2005)|
|10.||Houlé, John D: 4 articles (01/2013 - 05/2008)|
|1.||Melanoma (Melanoma, Malignant)
05/15/1995 - "In this study, we evaluated the potential role for a specific melanoma-associated chondroitin sulfate proteoglycan core protein, termed NG2, to collaborate with alpha 4 beta 1 integrin in focal contact formation in human melanoma cells. "
11/01/1986 - "Immunolocalization studies using whole-mount electron microscopy revealed that the chondroitin sulfate proteoglycan was present almost exclusively on microspikes, a microdomain of the melanoma cell surface. "
10/25/1984 - "Monoclonal antibody (Mab) 9.2.27 was utilized in a combination of biosynthetic and biochemical investigations as an immunological probe for the study of chondroitin sulfate proteoglycans (CSP) in human melanoma cells. "
03/01/2015 - "CSPG4-negative melanoma cell line WM1552C was transfected with CSPG4 and CSPG4 lacking cytoplasmic domain (melanoma-associated chondroitin sulfate proteoglycan (MCSP)ΔCD). "
12/01/2011 - "These cells located in the basal layer were negative for connexin-43 and positive for melanoma-associated chondroitin sulfate proteoglycan, containing holoclones with 0.2% CFE, thus representing the SC population. "
11/01/2012 - "The aim of this study was to analyze the potential role of NG2 chondroitin sulfate proteoglycan in amoeboid morphology and invasiveness of cancer cells. "
08/01/2014 - "Contributions of chondroitin sulfate proteoglycans to neurodevelopment, injury, and cancer."
09/25/2013 - "Specifically, noninvasive lesions are associated with a rich matrix containing substantial amounts of glycosylated chondroitin sulfate proteoglycans (CSPGs), whereas glycosylated CSPGs are essentially absent from diffusely infiltrating tumors. "
10/01/2012 - "We provide evidence that one third of BM-derived GFP(+) cells infiltrating the tumor expressed the chondroitin sulfate proteoglycan NG2 (pericytic marker) or α-smooth muscle actin (α-SMA, myofibroblast marker), whereas almost 90% of Thy1(+) fibroblasts were originating from resident GFP-negative cells. "
08/01/2007 - "The system developed was tested by assaying for chondroitin sulfate proteoglycans in sera from patients with various cancers and comparing the results to those obtained for sera from healthy people. "
09/24/1993 - "Recent studies have shown that in glioma cells, most of the soluble secreted APP occurs as a chondroitin sulfate proteoglycan (CSPG). "
09/25/2009 - "Chondroitin sulfate proteoglycans (CSPGs) are among the major inhibitory components in the neural matrix, but surprisingly, some are up-regulated in gliomas and act as pro-invasive signals. "
08/01/1999 - "The expression and function of NG2, a transmembrane chondroitin sulfate proteoglycan was studied in human gliomas of various histological types in culture using immunocytochemistry and flow cytometry. "
08/01/1995 - "Previously, we showed that in C6 glioma cell cultures, secreted APP nexin II occurs as the core protein of a chondroitin sulfate proteoglycan (CSPG). "
05/14/1993 - "Here we present evidence that full length APP-chondroitin sulfate proteoglycan is present on the cell surface of C6 glioma cells. "
09/04/2015 - "Chondroitin sulfate proteoglycans (CSPGs) are highly expressed by reactive scars and are potent contributors to the non-permissive environment in mature CNS. "
08/05/2015 - "This is due to: (1) the presence of inhibitory molecules, e.g., chondroitin sulfate proteoglycans (CSPG), in the glial scar at the lesion; and (2) the diminished growth capacity of adult neurons. "
08/01/2015 - "We previously demonstrated that injury-induced upregulation of matrix chondroitin sulfate proteoglycans (CSPGs) restricts the survival, migration, integration, and differentiation of NPCs following SCI. CSPGs are long-lasting components of the astroglial scar that are formed around the lesion. "
01/01/2015 - "Extracellular matrix molecule chondroitin sulfate proteoglycans (CSPGs) are highly upregulated in scar tissues and form a potent chemical barrier for CNS axon regeneration. "
10/01/2014 - "Astrogliosis and glial scar deposition, measured by GFAP-positive and chondroitin sulfate proteoglycan-positive volume, was significantly reduced. "
|5.||Spinal Cord Injuries (Spinal Cord Injury)
12/03/2014 - "NG2 is purportedly one of the most growth-inhibitory chondroitin sulfate proteoglycans (CSPGs) produced after spinal cord injury. "
04/02/2014 - "Chondroitin sulfate proteoglycans (CSPGs) inhibit repair following spinal cord injury. "
04/02/2014 - "Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury."
02/01/2013 - "Conditional Sox9 ablation reduces chondroitin sulfate proteoglycan levels and improves motor function following spinal cord injury."
06/01/2011 - "As a physical barrier to regenerating axons, reactive astrogliosis is also a biochemical barrier which can secrete inhibitory molecules, including chondroitin sulfate proteoglycans (CSPGs) in the pathological mechanism of spinal cord injury (SCI). "
|3.||Immunoglobulin G (IgG)
|6.||Hyaluronic Acid (Hyaluronan)
|8.||Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)
|9.||Amyloid (Amyloid Fibrils)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Homologous Transplantation (Allograft)
|5.||Transplantation (Transplant Recipients)